证券代码：301263 证券简称：泰恩康 公告编号：2025-041 广东泰恩康医药股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 广东泰恩康医药股份有限公司（以下简称"公司"）第五届董事会第八次会 议（以下简称"会议"）通知于 2025 年 6 月 19 日以书面送达或电子邮件方式向 全体董事发出，会议于 2025 年 6 月 26 日在公司会议室以通讯表决方式召开。 会议由董事长郑汉杰先生召集主持，本次会议应出席董事 7 人，实际出席董事 7 人，全部监事和高级管理人员列席会议。 本次董事会会议召集、召开符合《中华人民共和国公司法》《公司章程》等 的规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于使用自有资金支付募投项目部分款项并以募集资金 等额置换的议案》 经审议，同意公司在募投项目实施期间，使用自有资金支付募投项目相关 款项，后续以募集资金进行等额置换，即从募集资金专户划转等额资金至公司 一般账户，该部分等额置换资 ...

Core Viewpoint - The announcement of the second employee stock ownership plan by TianKang aims to enhance long-term incentive mechanisms, improve employee cohesion and corporate competitiveness, and deeply bind the interests of the company, shareholders, and employees [1] Summary by Relevant Sections Employee Stock Ownership Plan - The scale of the employee stock ownership plan is set between RMB 150 million and RMB 200 million, with an average purchase price based on the closing price of RMB 33.77 per share on June 20, 2025, leading to a minimum of approximately 4.44 million shares and a maximum of about 5.92 million shares, accounting for no more than 1.39% of the total share capital as of the announcement date [1] - The holding period for the stock is strictly regulated, with a minimum of 12 months required [1] Market Confidence and Stock Performance - Industry insiders highlight three key points regarding TianKang's equity incentive: the stock will be sourced through secondary market purchases, the buy-in scale is significant, and the plan reflects strong confidence in future development [2] - TianKang's stock price has surged by 130% this year, ranking fourth among innovative drug concept stocks [2] Innovation and Clinical Development - The collective rise of innovative drug leaders reflects a systematic re-evaluation of the long-term value of R&D investments, driven by expectations of industry upgrades rather than solely academic data disclosures [3] - TianKang's innovative drug CKBA for vitiligo has completed 100% subject enrollment in its Phase II clinical trial, with plans to explore additional indications in the next 3-5 years [3] Growth Areas - The company is focusing on several growth areas, including gastrointestinal drugs, sexual health, and ophthalmology [4] - In the gastrointestinal sector, TianKang aims to expedite the registration process for its product and target over RMB 1 billion in sales within 3-5 years [4] - The sexual health segment features leading products with significant market presence, and a new product is expected to enhance the company's portfolio [4] - In ophthalmology, the company is progressing with clinical trials for a product aimed at treating presbyopia, which could become the first of its kind in China [4] Overall Outlook - TianKang's employee stock ownership plan reflects the company's strong confidence in future growth, driven by innovation and clinical needs, while building high-value competitive barriers in core areas [5] - As key projects move towards commercialization, the company is expected to generate new performance growth points and enter a new growth cycle [5]

智通财经6月20日电，泰恩康(301263.SZ)公告称，公司全资子公司安徽泰恩康制药有限公司收到国家药 监局签发的硫酸氨基葡萄糖胶囊境内生产药品注册上市许可申请《受理通知书》。硫酸氨基葡萄糖胶囊 适用于原发性及继发性骨关节炎，原研药于1982年在意大利获批上市，1996年在中国获批上市。根据米 内网数据显示，2024年国内城市和县级公立医院、城市和网上药店、城市社区医院和乡镇卫生院的销售 金额约33.62亿元人民币。目前国内共有13家企业获得药品注册证书。 泰恩康：全资子公司收到硫酸氨基葡萄糖胶囊药品注册受理通知书 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-039 广东泰恩康医药股份有限公司 关于筹划第二期员工持股计划的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为进一步完善广东泰恩康医药股份有限公司（以下简称"泰恩康"或"公 司"）长效激励机制，提高员工的凝聚力和公司竞争力，实现公司、股东和员 工利益的一致性，促进公司持续、稳定及健康发展，根据《中华人民共和国公 司法》《中华人民共和国证券法》《关于上市公司实施员工持股计划试点的指 导意见》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等有关法律、法规及规范性文件的规定，结合公司实际情况，公司 拟推出第二期员工持股计划，相关筹划情况如下： 三、拟筹划的员工持股计划的持有人范围 本次拟筹划的员工持股计划持有人范围原则上为公司董事（不含独立董 事）、高级管理人员及公司（含合并报表范围内子公司）其他核心人员。具体 范围以后续审议披露的员工持股计划草案和员工实际缴纳出资为准。 四、预计披露本次员工持股计划草案的时间 董事会审议及披露本次员工持股计划草案的时间自本公告 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-040 广东泰恩康医药股份有限公司 申请事项：境内生产药品注册上市许可 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司安徽泰恩 康制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的硫酸氨基葡萄糖胶囊境内生产药品注册上市许可申请《受理通知书》， 国家药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药 品的药品注册上市许可申请进行了审查，决定予以受理。现将相关情况公告如 下： 一、申请注册药品的基本情况 受理号：CYHS2502208 许可药品注册分类：化学药品 4 类 规格：0.25g（以硫酸氨基葡萄糖计）或 0.314g（以氯化钠硫酸氨基葡萄糖 计） 申请人：安徽泰恩康制药有限公司 药品名称：硫酸氨基葡萄糖胶囊 经查询国家药监局网站数据，截至目前硫酸氨基葡萄糖胶囊在国内共有 13 家企业获得药品注册证书。 四、对公司的影响及风险提示 根据国家相关法规规定，上述药品 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-038 本员工持股计划的锁定期已于 2025 年 5 月 6 日届满，具体情况详见公司于 2025 年 5 月 7 日披露于巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 二、本员工持股计划减持情况 本员工持股计划于 2025 年 6 月 4 日至 2025 年 6 月 20 日期间，通过集中竞 价交易方式累计减持公司股票 5,694,348 股，占公司总股本的 1.3383%。 截至本 公告披露日，本员工持股计划所持公司股票已全部减持完毕。 三、其他相关说明 减持期间，公司严格遵守市场交易规则及中国证监会关于信息敏感期不得 买卖股票的规定， 不存在利用内幕信息进行交易的情形。 广东泰恩康医药股份有限公司 关于 2024 年员工持股计划减持完毕的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、本员工持股计划基本情况 广东泰恩康医药股份有限公司（以下简称"公司"）于 2024年 3月 27日召 开第五届董事会第二次会议和第五届监事会第二次会议，于 2024年 ...

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Core Insights - The hair medical concept sector has seen a rise of 2.25%, ranking third among concept sectors in terms of growth [1] - Within this sector, 11 stocks increased in value, with notable performers including Aoyang Health, Kanghui Pharmaceutical, and *ST Meigu, which reached their daily limit [1] - The sector experienced a net inflow of 64 million yuan from main funds, with Aoyang Health leading the inflow at 68.73 million yuan [2][3] Sector Performance - The hair medical concept sector's performance is highlighted by the following stocks: - Aoyang Health: increased by 10.12% with a turnover rate of 26.84% and a net inflow of 68.73 million yuan [3] - Taiankang: increased by 9.35% with a turnover rate of 10.42% and a net inflow of 51.69 million yuan [3] - Kanghui Pharmaceutical: increased by 9.99% with a turnover rate of 4.06% and a net inflow of 33.06 million yuan [3] - Huailong Co.: increased by 3.35% with a turnover rate of 11.07% and a net inflow of 14.87 million yuan [3] Fund Flow Analysis - The top stocks by net inflow ratio in the hair medical sector include: - Kanghui Pharmaceutical: net inflow ratio of 36.67% [3] - *ST Meigu: net inflow ratio of 11.74% [4] - Aoyang Health: net inflow ratio of 7.40% [3] - The overall trend indicates a strong interest from main funds in the hair medical sector, with several stocks showing significant inflows [2][3]

10日，A股、港股午后全线回落，创业板指、科创50指数等跌超1%，恒生科技指数跌近1%。 具体来看，两市股指早盘窄幅震荡，午后加速下探。截至收盘，沪指跌0.44%报3384.82点，深证成指跌0.86% 报10162.18点，创业板指跌1.17%报2037.27点，科创50指数跌1.47%，北证50指数跌约1%，沪深北三市合计成 交14516亿元，较此前一日增加近1400亿元。 场内超4000股飘绿，半导体、军工、石油、券商、酿酒等板块走低；银行板块走强，民生银行一度涨约4%， 兴业银行、南京银行盘中创出新高；农业板块拉升，种业股表现亮眼，秋乐种业、康农种业涨超10%；离境退 税概念崛起，国航远洋30%涨停，宁波海运、南京港、连云港等涨停；创新药概念再度活跃，昂利康连续3日 涨停，一品红、泰恩康涨超9%均创出新高；稀土概念持续强势，中科磁业、科恒股份等涨停；短剧概念尾盘 异动，中文在线涨超13%，慈文传媒涨停；体育概念热度不减，共创草坪斩获7连板。 离境退税概念盘中大幅走高，截至收盘，国航远洋30%涨停，华光源海涨近27%，宁波远洋、南京港、连云港 等均涨停。 | 代码 | 名称 | 4 | 涨幅% | 现价 ...